Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells
Authors:
- Alexander HuetherAHAlexander Huether
- Andreas P. SutterASAndreas P. Sutter
- Viola BaradariVBViola Baradari
- Detlef SchuppanDSDetlef Schuppan
- Hans ScherüblHSHans Scherübl
- 1 May 2006
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 71 (10) , 1435-1448
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Environmental factors and risk for hepatocellular carcinomaGastroenterology, 2004
- Obesity and hepatocellular carcinomaGastroenterology, 2004
- The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An UpdateAnnals of Internal Medicine, 2003
- The Role of the IGF Axis in HepatocarcinogenesisHormone and Metabolic Research, 2003
- Focal overexpression of insulin-like growth factor 2 by hepatocytes and cholangiocytes in viral liver cirrhosisBritish Journal of Cancer, 2003
- Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosisWorld Journal of Gastroenterology, 2003
- Insulin-Like Growth Factor Receptor-1 as an Anti-Cancer Target: Blocking Transformation and Inducing ApoptosisCurrent Cancer Drug Targets, 2002
- International trends and patterns of primary liver cancerInternational Journal of Cancer, 2001
- Trends in Survival of Patients With Hepatocellular Carcinoma Between 1977 and 1996 in the United StatesHepatology, 2001
- Oncogenes and the strategy of growth factorsCell, 1994